ClinicalTrials.gg
TerminatedNCT02479880Updated May 20, 2019Results posted

Utilization and Efficacy of Tenofovir DF in Adolescents With Chronic Hepatitis B Virus Infection

A Phase 4 interventional study of Tenofovir DF and DEXA Scan in Hepatitis B, sponsored by Gilead Sciences. Terminated at 11 sites in 7 countries. Open to participants aged 12 Years to 15 Years. Per ClinicalTrials.gov, last updated 2019-05-20.

Sponsored by Gilead Sciences · Phase 4, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
12 Years to 15 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 41 studies testing tenofovir in Hepatitis B — none open to participants now, 4 under way, 2 of them phase 3. Tenofovir · Hepatitis B.

Enrollment
35th of 41
30 · median 100
Started
2015
with 5 others
Phase 4
14 of 41
none open now
Registered
23rd of 41
by date
Lead sponsor
7 of 41
Gilead Sciences

Among the 41 studies testing tenofovir in Hepatitis B, this one is the 35th largest by enrollment, is one of 6 that started in 2015, is one of 14 in phase 4, and was the 23rd registered.

Hepatitis B

1,046 studies on the registry are indexed under Hepatitis B; 139 are open to participants now.

Browse Hepatitis B studies →

Open to participants now

None of the 41 studies testing tenofovir in Hepatitis B is open now. The open studies under Hepatitis B, anywhere →

About tenofovir

Tenofovir: first FDA approval 2001 (VIREAD), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 80 Hepatitis B studies recruiting now, 40 (50%) set no upper age limit and 35 (44%) stop at 75 or younger; 14 take children under 18; 20 take healthy volunteers.

This study: 12 Years to 15 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 41 studies testing tenofovir in Hepatitis B as a file.
02

Study summary

The primary objective of this study is to characterize the long term (ie, 96 weeks of follow up) bone safety profile of open-label tenofovir disoproxil fumarate (tenofovir DF) treatment in CHB-infected adolescents. This includes prospectively evaluating and comparing the bone mineral density (BMD) change between CHB-infected adolescents 12 to \< 18 years of age treated with tenofovir DF in European treatment centers who are assigned to one of two schedules for renal and bone laboratory monitoring and BMD measurement.

03

Conditions studied

  • Hepatitis B

Browse trials for

04

Who can participate

Ages eligible
12 Years to 15 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. 12 to \<16 years of age
  2. Documented chronic virus (HBV) infection
  3. Weight ≥ 35 kg
  4. Able to swallow oral tablets
  5. Negative pregnancy test for females of
  6. Adequate kidney (renal) function
  7. Parent or legal guardian of potential study subjects able to provide written

Key Exclusion Criteria:

  1. Previously received tenofovir DF
  2. Sexually-active males or females of who are not willing to use an effective method of during the study
  3. Females who are pregnant or breastfeeding, or females who wish to become pregnant during the course of the study
  4. Known to tenofovir DF, the metabolites or formulation
  5. Any condition (including alcohol or substance abuse) or prior therapy that, in the opinion of the Investigator, would make the subject unsuitable for the study or unable to comply with treatment requirements

Note: Other protocol defined Inclusion/Exclusion criteria may apply

Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 4
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
30 participants (actual)

Study arms

  • Other
    Tenofovir DF + increased bone/renal monitoring

    Participants will receive tenofovir DF, plus laboratory bone biomarker testing and lumbar spine and whole-body DEXA scans every 24 weeks from baseline to Week 96 (5 scans), and monitoring of renal function at 4 and 12 weeks after baseline and every 12 weeks thereafter. With the exception of an enhanced monitoring protocol for bone and renal outcomes, participants will be managed according to local standards of care.

    Drug: Tenofovir DF · Radiation: DEXA Scan

  • Other
    Tenofovir DF + prespecified bone monitoring

    Participants will receive tenofovir DF, plus laboratory bone biomarker testing and lumbar spine and whole-body DEXA scans at baseline, Week 48, and Week 96. With the exception of pre-specified bone monitoring, participants will be managed according to local standards of care.

    Drug: Tenofovir DF · Radiation: DEXA Scan

Interventions

  • 300 mg tablet administered orally once daily for up to 96 weeks

    Also known as: Viread®

  • RadiationDEXA Scan

    Dual energy x-ray absorptiometry (DEXA) scans administered at protocol-specified time points

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Bone-Related Adverse Events and/or a ≥ 4% Reduction in Bone Mineral Density (BMD) From Baseline to Week 96

    Time frame: Baseline to Week 96

07

Results

Posted May 20, 2019

Participant flow

Participants were enrolled at study sites in Europe. The first participant was screened on 03 July 2015. The last study visit occurred on 11 April 2018. The study did not achieve targeted enrollment as it was prematurely terminated by the Pharmacovigilance Risk Assessment Committee (PRAC).

Participant flow — Overall Study
MilestoneTenofovir DF + Increased Bone/Renal MonitoringTenofovir DF + Prespecified Bone Monitoring
Started1515
Completed22
Not completed1313
Withdrew: Study terminated by sponsor1312
Withdrew: Pregnancy01

Outcome measures

PrimaryPercentage of Participants With Bone-Related Adverse Events and/or a ≥ 4% Reduction in Bone Mineral Density (BMD) From Baseline to Week 96
Time frame:
Baseline to Week 96
Reported as:
Number · percentage of participants
Percentage of Participants With Bone-Related Adverse Events and/or a ≥ 4% Reduction in Bone Mineral Density (BMD) From Baseline to Week 96
percentage of participantsTenofovir DF + Increased Bone/Renal MonitoringTenofovir DF + Prespecified Bone Monitoring
Percentage of Participants With Bone-Related Adverse Events and/or a ≥ 4% Reduction in Bone Mineral Density (BMD) From Baseline to Week 966.70

Adverse events

Collected over Up to 96 weeks plus 30 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Tenofovir DF + Increased Bone/Renal Monitoring0/15 (0%)1/15 (6.7%)10/15 (66.7%)
Tenofovir DF + Prespecified Bone Monitoring0/15 (0%)2/15 (13.3%)10/15 (66.7%)
Most frequent serious events
Most frequent serious events
EventTenofovir DF + Increased Bone/Renal MonitoringTenofovir DF + Prespecified Bone Monitoring
CalcinosisGeneral disorders1/150/15
MalaiseGeneral disorders0/151/15
Abortion spontaneousPregnancy, puerperium and perinatal conditions0/151/15
Most frequent other events
Showing 10 of 31
Most frequent other events
EventTenofovir DF + Increased Bone/Renal MonitoringTenofovir DF + Prespecified Bone Monitoring
Abdominal painGastrointestinal disorders1/152/15
VomitingGastrointestinal disorders2/150/15
PyrexiaGeneral disorders2/150/15
NasopharyngitisInfections and infestations2/150/15
Bone density decreasedInvestigations0/152/15
Vitamin D decreasedInvestigations2/152/15
HeadacheNervous system disorders0/152/15
Abdominal pain lowerGastrointestinal disorders0/151/15
Abdominal pain upperGastrointestinal disorders0/151/15
Anal fissureGastrointestinal disorders1/150/15

Baseline characteristics

Safety Analysis Set included participants who were randomized into the study and received at least one dose of tenofovir DF.

Age, Continuous
Age, Continuous(years)Tenofovir DF + Increased Bone/Renal MonitoringTenofovir DF + Prespecified Bone MonitoringTotal
Mean14 ± 1.414 ± 1.514 ± 1.4
Sex: Female, Male
Sex: Female, Male(Participants)Tenofovir DF + Increased Bone/Renal MonitoringTenofovir DF + Prespecified Bone MonitoringTotal
Female5510
Male101020
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Tenofovir DF + Increased Bone/Renal MonitoringTenofovir DF + Prespecified Bone MonitoringTotal
Hispanic or Latino131225
Not Hispanic or Latino011
Unknown or Not Reported224
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Tenofovir DF + Increased Bone/Renal MonitoringTenofovir DF + Prespecified Bone MonitoringTotal
Asian257
Black or African American5510
White7411
Other112
Region of Enrollment
Region of Enrollment(participants)Tenofovir DF + Increased Bone/Renal MonitoringTenofovir DF + Prespecified Bone MonitoringTotal
Greece112
Romania448
Belgium224
Italy101
United Kingdom246
France213
Spain336
08

Study locations

11 sites
  • Cliniques Universitaries Saint- Luc, Departem Pediatrie
    Brussels, 1200, Belgium
  • Hopital Femmes Meres Enfants
    Bron, 69677, France
  • Attikon General Hospital Of Athens
    Chaidari, 12462, Greece
  • Azienda Ospedaliero-Universitaria di Bologna
    Bologna, 40138, Italy
  • Grigore Alexandrescu Childrens Emergency Clinical Hospital
    Bucharest, 11743, Romania
  • Spitatul Clinic de Boli Infectioase Constanta
    Constanta, 900708, Romania
  • Institutul de Gastrenterologie si Hepatologie Iasi
    Iaşi, 700111, Romania
  • Hospital Universitari Germans Trias i Pujol
    Badalona, Barcelona 08916, Spain
  • Hospital Sant Joan de Déu
    Barcelona, 8950, Spain
  • Hospital de Meixoeiro
    Vigo, 36200, Spain
  • Birmingham Children's Hospital NHS Trust
    Birmingham, B4 6NH, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2015 to primary completion in Feb 2018, 31 months.

Results were first posted in May 2019, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 17, 2015
First posted
Jun 24, 2015
StartActual
Jul 3, 2015
Primary completionActual
Feb 28, 2018
CompletionActual
Apr 11, 2018
Results first posted
May 20, 2019
Last update
May 20, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 20, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02479880
Lead sponsor
Gilead Sciences
Responsible party
Sponsor
First posted
Jun 24, 2015
Start date
Jul 3, 2015
Primary completion
Feb 28, 2018
Completion
Apr 11, 2018
Results posted
May 20, 2019
Last update
May 20, 2019

Study contacts

Gilead Study Director
study director · Gilead Sciences

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Feb 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tenofovir

Start the discussion